Previous Article | Next Article 
Journal of Clinical Microbiology, September 2000, p. 3306-3310, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Quantitative Competitive Reverse Transcription-PCR
for Quantification of Dengue Virus RNA
Wei-Kung
Wang,1,*
Chun-Nan
Lee,2
Chuan-Liang
Kao,2
Yi-Ling
Lin,3 and
Chwan-Chuen
King4
Institute of
Microbiology,1 Graduate Institute of
Medical Technology,2 and College of
Medicine, Institute of Epidemiology,4
College of Public Health, National Taiwan University, and
Institute of Biomedical Sciences, Academia
Sinica,3 Taipei, Taiwan
Received 11 February 2000/Returned for modification 19 May
2000/Accepted 5 July 2000
 |
ABSTRACT |
A quantitative competitive reverse transcription-PCR assay was
developed to quantify dengue virus RNA in this study. The main features
include a primer pair targeting a highly conserved region in the capsid
and the addition of competing RNA that contains an internal deletion to
provide a stringent internal control for quantification. It can be
utilized to quantify RNA isolated from the four dengue virus serotypes
but not RNA isolated from other flaviviruses, including Japanese
encephalitis virus and hepatitis C virus, both prevalent in Asia. It
can also be used to quantify dengue virus RNA isolated from the plasma
of infected individuals. The sensitivity of the assay was estimated to
be 10 to 50 copies of RNA per reaction, and twofold differences in
virus titer are distinguishable. This assay is a convenient, sensitive,
and accurate method for quantification and can be used to further
understanding of the pathogenesis of dengue virus infection.
 |
INTRODUCTION |
Among the 70 or so arthropod-born
flaviviruses, epidemics of the four dengue viruses (DEN-1, DEN-2,
DEN-3, and DEN-4) continue to be a major public health problem in
tropical and subtropical regions (1, 8, 11, 21). It has been
estimated that about 100 million cases of dengue fever (DF) and 250,000 cases of dengue hemorrhagic fever occur annually worldwide (8,
21).
The clinical presentations of the four dengue virus serotypes are
similar. They range from mild, self-limited DF to severe and
potentially life-threatening dengue hemorrhagic fever-dengue shock
syndrome (8, 11, 30). Following an incubation period, there
are fever and a variety of symptoms, which concur with the appearance
of dengue virus in blood (8). Detection and quantification of dengue virus in plasma are not only crucial for rapid diagnosis but
can also add to our understanding of the pathogenesis of dengue (8, 11). Several techniques have been developed to detect dengue viremia (2, 4, 8, 9, 14, 26, 29). The conventional
method is virus isolation, although it is time-consuming and has
variable isolation rates (4, 8, 29). The reverse transcription (RT)-PCR assays are more rapid and sensitive, but many of
them require separate procedures for RT and PCR (4, 8, 26,
29). The recently reported TaqMan amplification system employs
the one-step RT-PCR protocol and is a sensitive method for
quantification (16).
Quantification based on the standard RT-PCR method, however, has
certain limitations (5, 22, 25). First, the amount of
product does not consistently reflect the amount of the initial target.
This is probably due to differential efficiencies and kinetics of PCR
and/or RT depending on the abundance of the target and the presence of
various inhibitors, particularly in clinical samples (5,
22). Second, comparison of the amount amplified from the specimen
to that from a titrated standard in separate reactions is not ideal for
quantification. Third, normalization by coamplifying a heterologous
target (such as actin or
-globulin) cannot provide a good internal
control because of differences in abundance and the priming efficiency
of the heterologous target (5, 22).
In the quantitative competitive RT-PCR (QC-RT-PCR) assay, increasing
amounts of competing RNA that is largely identical, but somewhat
distinguishable (containing an internal deletion) from the target
sequence, are added to replicate tubes that contain the same amounts of
the target sequence (5, 22). The competing RNA and target
RNA are in the same tube and provide a stringent internal control.
After electrophoresis, the different-size RT-PCR products are
quantified. The amounts of the target sequence are determined based on
the relative, not the absolute, amounts of the products by either
direct or interpolated assessment of the equivalent point (5,
22). In this report, we describe a sensitive and convenient
QC-RT-PCR assay that can quantify dengue virus RNA of all four serotypes.
 |
MATERIALS AND METHODS |
Generation of the construct and competitor RNA.
CPrM/pCR3.1
is a plasmid containing the entire capsid (C) region and the N-terminal
54 amino acids of the precursor membrane (PrM) region of DEN-2 strain
PL046 in the vector pCR3.1 (Invitrogen, San Diego, Calif.)
(17) (Fig. 1). The competitor
construct Cd40PrM/pCR3.1 was modified from CPrM/pCR3.1 by digestion
with two restriction enzymes, SalI and BsmI, in
the C region, followed by filling of the 3' recessed end (from the
SalI cut) and removal of the 5' protruding end (from the
BsmI cut) with T4 DNA polymerase (Fig. 1). Compared to
CPrM/pCR3.1, Cd40PrM/pCR3.1 had a 40-bp internal deletion in the C
region, as was verified by DNA sequencing. Competitor RNA, Cd40PrM,
which was generated from in vitro transcription (Promega, Madison,
Wis.) of linearized Cd40PrM/pCR3.1, was purified by phenol-chloroform
extraction and quantified by spectrophotometer. The copy number of
Cd40PrM was calculated based on the concentration measured and its
molecular weight. Wild-type RNA, CPrM, was similarly generated from
linearized CPrM/pCR3.1 and quantified by spectrophotometer. The copy
number of CPrM was thus calculated, and known amounts of CPrM were used
as target RNA in the QC-RT-PCR assay.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic diagram of the construct containing wild-type
dengue virus CPrM sequences, CPrM/pCR3.1 (top) and the competitor
construct containing an internal deletion of CPrM, Cd40PrM/pCR3.1
(bottom). The relative positions of the primers used for the QC-RT-PCR
assay, C14A and C69B, are shown. 5' NTR, 5' nontranslated region.
|
|
Isolation of viral RNA.
Dengue virus RNA was isolated from
aliquots of culture supernatants or plasma using the QIAamp viral RNA
mini kit (Qiagen). Plasma samples were obtained within 24 h of the
onset of fever from two confirmed DF patients during a DEN-3 outbreak
in southern Taiwan in 1998. Plasma samples were also obtained from two
hepatitis C virus (HCV) carriers and two healthy individuals. Stock
viruses of the four dengue virus serotypes, the Hawaii (DEN-1), New
Guinea (DEN-2), H-87 (DEN-3), and H-241 (DEN-4) strains, had titers of 2.1 × 106, 1.3 × 106, 2 × 106, and 1 × 106 PFU/ml, respectively.
They were obtained from culture supernatants of infection of mosquito
C6/36 cells and then titrated on BHK-21 cells by standard
plaque-forming assay. Three Japanese encephalitis virus (JEV) strains
(the Nakayama vaccine strain, the Beijing vaccine strain, and the
CH1949 Taiwan local strain isolated from Changhwa County) with titers
of 105 to 106 PFU/ml were also used for
comparison, since JEV is another prevalent flavivirus circulating in
Taiwan. Stock virus dilutions of 1- to 100-fold were used to isolate
viral RNA for RT-PCR detection. For QC-RT-PCR quantification, 1- to
10,000-fold dilutions of the Hawaii strain virus and serial 2-fold
dilutions thereafter were also prepared and subjected to virus RNA
isolation. Briefly, a 140-µl volume of plasma or diluted stock virus
was mixed with the buffer AVL-carrier RNA and loaded onto the spin
column. This was followed by a wash with the buffer AW and elution with
the buffer AVE to a final volume of 50 µl, as recommended by the
manufacturer (Qiagen).
RT-PCR primers.
Despite the sequence variation observed
among different dengue viruses, certain regions in the dengue virus
genome are more conserved than other regions (12, 14, 20).
Through an analysis of all of the dengue virus sequences available in
the GenBank database, a region in the C that is highly conserved in the
four dengue viruses, but not in other flaviviruses, was identified. A
primer pair covering this region, C14A and C69B, was thus designed for
the QC-RT-PCR assay. The sequences of C14A and C69B are
5'-AATATGCTGAAACGCGAGAGAAACCGCG-3' (corresponding to genome
positions 136 to 163 of the DEN-2 Jamaica strain) and
5'-CCCATCTCITCAIIATCCCTGCTGTTGG-3' (corresponding to genome
positions 278 to 305 of the DEN-2 Jamaica strain), respectively (3, 14). They were designed to amplify a 170-bp product in the C region for dengue virus RNA or a 130-bp product in the same region for competitor RNA Cd40PrM.
QC-RT-PCR.
For adequate quantification, eluates containing
RNA templates isolated from plasma were further diluted 10-fold. Equal
amounts (2 µl) of the RNA eluates or diluted eluates were mixed with
increasing copy numbers of competitor RNA Cd40PrM (0, 10, 50, 100, 500, 1,000, 5,000, and 10,000 copies) and subjected to RT-PCR using the
Superscript one-step RT-PCR system (Gibco/BRL, Life Technologies). The
RT-PCR conditions were 55°C for 40 min and 94°C for 2 min, followed
by 40 cycles of 94°C for 45 s, 65°C for 45 s, and 68°C
for 45 s. For the control reaction of PCR only, RNA eluate (2 µl) was subjected to PCR using super Taq DNA polymerase
(HT Biotechnology, Cambridge, England) under PCR conditions identical
to those used in the RT-PCR, except that the step using 55°C for 40 min was omitted.
Sample analysis and quantification.
The QC-RT-PCR products
were electrophoresed through 2% agarose gel and stained with ethidium
bromide. The amounts of the 170- and 130-bp products were measured
under UV light using a digital gel documentation and analysis system
consisting of a UV-transilluminator light box, a darkroom cabinet, and
a DigiPix (Ultralum, Paramount, Calif.) digital camera. The image
acquired with the digital camera was sent to the computer directly and
analyzed by the 1D scan (Scanalytics, Fairfax, Va.) software. The
intensity of the ethidium fluorescence associated with the DNA band is
proportional to the amount of DNA. The RT-PCR product of the wild-type
target RNA is 170 bp, and that of the competitor RNA, Cd40PrM, is 130 bp. Since the comparisons in the QC-RT-PCR were based on molar amounts, the fluorescence intensity of the 130-bp product was corrected by a
factor of 170/130 to enable direct comparison of the corrected intensity of the 130-bp competitor (Cor. Int. 130) with the
fluorescence intensity of the 170-bp target (Int. 170). The ratio of
the Cor. Int. 130 to the Int. 170 (log scale) was plotted against the
copy number of the competitor RNA (log scale). A regression line with the coefficient of determination, R2, was
generated. The copy numbers of dengue virus RNA per reaction were
determined by interpolated assessment of the equivalence point of the
above curve. The 95% confidence intervals (CI) of the copy numbers
were calculated using the software SPSS base 8.0 (SPSS Inc., Chicago,
Ill.). Since 2 µl out of 50 µl of RNA eluates, which were derived
from 140 µl of culture supernatant or plasma, was used in each
reaction, the number of dengue virus RNA copies per reaction was
divided by 5.6 µl (140 µl × 2 µl/50 µl) and multiplied by
1,000 to obtain the number of RNA copies per milliliter of supernatant
or plasma.
Sequencing of RT-PCR products.
The 170-bp products derived
from QC-RT-PCR were cloned into the TA cloning vector pCRII-TOPO using
the procedures recommended by the manufacturer (Invitrogen, Carlsbad,
Calif.). Plasmids containing the inserts were sequenced using the
BigDye terminator cycle sequencing kit under the conditions recommended
by the manufacturer (PE Applied Biosystems, Foster City, Calif.).
Samples were loaded onto 4.75% polyacrylamide gel of ABI automated
sequencers (Applied Biosystems ABI-373A; Perkin-Elmer).
 |
RESULTS |
Detection of the four dengue virus serotypes.
A close
examination of the dengue virus sequences available in the GenBank
database revealed a small region in the C that was highly conserved in
isolates of all four dengue viruses but not in other flaviviruses. This
region was chosen as our target sequence, and primers covering this
region, C14A and C69B, were designed for the QC-RT-PCR assay.
Deoxyinosines, which are known to pair with all four bases except G,
were incorporated into primer C69B at three positions where variations
of A, T, and C were noted to maintain comparable priming efficiency.
To examine whether the designed primer pair can detect dengue virus
RNA, RNA templates derived from culture supernatants of viruses
representing the four dengue virus serotypes, including Hawaii (DEN-1),
New Guinea (DEN-2), H-87 (DEN-3), and H-241 (DEN-4), were subjected to
RT-PCR. As shown in Fig. 2, amplified
products of the expected size of 170 bp were seen in the reactions
using the RNA template derived from the four dengue viruses. There was no product seen in the reactions containing no RNA or when the RT step
was omitted (Fig. 2 and data not shown). RNA templates derived from
other flaviviruses prevalent in Taiwan, including three JEV and two
HCV, as well as from the plasma of two healthy individuals, were also
subjected to the RT-PCR assay. None of these resulted in any amplified
product of the expected size (data not shown). It was of note that the
RNA templates of JEV and HCV can be amplified by their homologous
primers (data not shown). These results were consistent with our
sequence analysis of the C region and indicated that the designed
primers, C14A and C69B, can detect the four dengue virus serotypes but
not the other flaviviruses tested.

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of the four dengue virus serotypes using the
designed primer pair. Dengue virus RNAs isolated from stock viruses of
the four serotypes were subjected to RT-PCR analysis as described in
Materials and Methods. Products with an expected size of 170 bp were
seen in the reactions using RNA templates derived from the DEN-1 Hawaii
strain (lane 2), the DEN-2 New Guinea strain (lane 3), the DEN-3 H-87
strain (lane 4), and the DEN-4 H-241 strain (lane 5) but not seen in
the reaction containing no RNA (lane 1). Lanes m, molecular size
marker.
|
|
Quantification of dengue virus RNA by QC-RT-PCR.
To assess the
feasibility of the QC-RT-PCR assay for quantification, known amounts of
in vitro-transcribed target RNA, CPrM, which contained the wild-type
dengue virus sequence, and Cd40PrM competitor RNA were used in the
QC-RT-PCR assay. As shown in Fig. 3,
addition of increasing amounts of Cd40PrM (from 0 to 10,000 copies) to
replicate reactions containing identical amounts of CPrM (300 copies)
resulted in a gradual increase in the intensity of RT-PCR products of
the competitor RNA (130 bp) and a gradual decrease in the Int. 170 of
the target RNA. The point where the intensity of the 130-bp product
derived from a known amount of competitor RNA corresponds to the Int.
170 in molar equivalence indicates the amount of target RNA present in
the sample. After correction of the fluorescence intensity of the
130-bp product by a factor of 170/130, the ratios of the Cor. Int. 130 to the Int. 170 on a log scale [log (Cor. Int. 130/Int. 170)] were
plotted against the copy number of competitor RNA on a log scale. A
regression line was obtained. The point at which the Cor. Int. 130/Int.
170 ratio equals 1 represents the amount of target RNA present in the
sample. The amount of target RNA, CPrM, was thus determined to be 302 copies (95% CI, 224 to 388 copies), which is very close to the actual
amount of 300 copies added in each reaction.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Quantification of dengue virus RNA by the QC-RT-PCR
assay. An ethidium bromide-stained gel of the QC-RT-PCR assay is shown.
Equal amounts (300 copies) of in vitro-transcribed target RNA, CPrM,
mixed with increasing copy numbers of competitor RNA, Cd40PrM, were
subjected to RT-PCR analysis as described in Materials and Methods.
Lanes: 1 to 8, 0, 10, 50, 100, 500, 1,000, 5,000, and 10,000 copies of
Cd40PrM, respectively; m, molecular size markers. The positions of the
expected products of CPrM (170 bp) and Cd40PrM (130 bp) are
indicated.
|
|
It should be noted that for reactions near the equivalent points (lanes
4 to 6, Fig. 3), there was a third band migrating more slowly than the
product of the target RNA CPrM (170 bp) and the product of the
competitor RNA Cd40PrM (130 bp). The slower migration pattern and the
prominence of the bands seen only in reactions near the equivalent
points between the target and competitor RNAs suggested that these
bands were heteroduplex complexes of the two different-size products.
The formation of such heteroduplexes should not affect the accuracy of
our quantification, as the quantification in the QC-RT-PCR is based on
the amount of the target RNA product relative to that of the competitor
RNA and not the absolute amount. In addition, both the target and
competitor products will, in principle, be similarly affected by
formation of the heteroduplex complex (5, 22).
To demonstrate the accuracy of quantification of the QC-RT-PCR assay,
different amounts of target RNA CPrM, ranging from 10 to 2,000 copies,
were tested in the QC-RT-PCR assay and the number of copies determined
was very close to the actual number of copies added to each reaction
mixture (data not shown). From continuing optimization of the assay,
its sensitivity was estimated to be 10 to 50 copies of RNA per reaction.
Quantification of dengue virus RNA in culture supernatants.
To
evaluate the QC-RT-PCR assay with samples more biologically relevant
than in vitro-transcribed RNA, RNA isolated from the Hawaii strain of
the DEN-1 virus was subjected to the QC-RT-PCR assay. As shown in Fig.
4, a gradual decrease in the intensity of
the products of the expected size (170 bp) and a gradual increase in
intensity of the 130-bp products of competitor RNA were seen as the
amounts of the competitor increased from 0 to 5,000 copies. The ratios
of the Cor. Int. 130 to the Int. 170 on a log scale [log (Cor. Int.
130/Int. 170)] were plotted against the copy number of the competitor
RNA on a log scale. Based on the regression line obtained, the amount
of RNA was determined to be 205 copies (95% CI, 109 to 388 copies) per
reaction, which corresponds to 36,607 copies of RNA per ml of
supernatant.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Quantification of dengue virus RNA derived from culture
supernatants. An ethidium bromide-stained gel of the QC-RT-PCR assay is
shown. Equal amounts of RNA eluates derived from culture supernatants
of a DEN-1 virus (Hawaii strain) were mixed with increasing copy
numbers of competitor RNA, Cd40PrM, and subjected to RT-PCR analysis as
described in Materials and Methods. Lanes: 1 to 7, 0, 10, 50, 100, 500, 1,000, and 5,000 copies of Cd40PrM, respectively; m, molecular size
markers. The positions of the expected products of dengue virus RNA
(170 bp) and Cd40PrM (130 bp) are indicated.
|
|
To further evaluate this QC-RT-PCR assay for the quantification of
dengue virus, serial twofold dilutions of the Hawaii strain of the
DEN-1 virus were subjected to viral RNA isolation and the RNA was
employed in the QC-RT-PCR assay. The RNA copy number was determined for
each dilution and plotted against the virus titer of each dilution. A
linear relationship was found between the determined RNA copy numbers
per milliliter of supernatant and the virus titer, expressed in PFU per
milliliter, and a twofold difference in virus titer can be
differentiated by this QC-RT-PCR assay. Taken together, these results
demonstrate the feasibility and accuracy of this assay for the
quantification of dengue viruses.
Quantification of plasma dengue virus RNA.
To examine whether
the QC-RT-PCR assay can be utilized to quantify dengue virus RNA
present in clinical specimens, plasma samples obtained from two DEN-3
virus-infected individuals were subjected to viral RNA isolation and
the RNA was subjected to the QC-RT-PCR assay. As shown in Fig.
5A, a gradual decrease in the intensity
of the 170-bp product of viral RNA obtained from patient 1 and a
gradual increase in the intensity of the 130-bp products of competitor
RNA were seen as the amount of the competitor increased from 0 to
10,000 copies. The ratios of the Cor. Int. 130 to the Int. 170 on a log
scale [log (Cor. Int. 130/Int. 170)] were plotted against the copy
number of competitor RNA on a log scale. A regression line was obtained
with the equation y = 0.8787x
1.9601, R2 = 0.9384. The amount of RNA was determined to
be 170 copies (95% CI, 89 to 359 copies) per reaction, which
corresponded to 303,570 copies of RNA per ml of plasma for patient 1. The results of the QC-RT-PCR assay for plasma virus RNA obtained from
another patient, patient 2, are shown in Fig. 5B. Based on the plot
generated and the regression line (y = 0.5124x
0.8156, R2 = 0.9359), the amount of RNA was
calculated to be 39 copies (95% CI, 18 to 115 copies) per reaction,
corresponding to 69,640 copies of RNA per ml of plasma. The identity of
the 170-bp RT-PCR products was confirmed to be dengue virus C region
after cloning and sequencing of the 170-bp bands for both patients
(data not shown).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 5.
Quantification of dengue virus RNA in plasma. (A and B)
Ethidium bromide-stained gels of the QC-RT-PCR assay for two DEN-3
virus-infected individuals, patients 1 (A) and 2 (B). Equal amounts of
RNA eluates derived from plasma were mixed with increasing copy numbers
of competitor RNA, Cd40PrM, and subjected to RT-PCR analysis as
described in Materials and Methods. Lanes: 1 to 8, 0, 10, 50, 100, 500, 1,000, 5,000, and 10,000 copies of Cd40PrM, respectively; m, molecular
size markers. The positions of the expected products of dengue virus
RNA (170 bp) and Cd40PrM (130 bp) are indicated.
|
|
 |
DISCUSSION |
In this study, we developed a sensitive QC-RT-PCR assay that can
quantify dengue virus RNA derived from culture supernatants and plasma
samples of dengue virus-infected individuals. Since outbreaks of dengue
frequently involve more than one serotype (8, 11, 18), a
quantitative method that can detect all four dengue virus serotypes
would be ideal and practical. Based on our sequence analysis, a primer
pair (C14A and C69B) targeting a region in the capsid highly conserved
by dengue viruses but not by other flaviviruses was designed in this
study. Among the 38 dengue virus C sequences available in the GenBank
database only 2 had two mismatches in the C14A primer region and
another 2 had three mismatches in the C69B primer region. The
mismatches were located primarily at the 5' half of the primers and are
therefore less likely to affect the RT-PCR significantly. Whether
strain variability of all field isolates would affect the performance of the assay remains to be examined.
C14A overlaps a previously reported consensus primer, D1, which, in
combination with another primer in the CPrM region, has been shown to
be dengue virus specific (14). While determination of the
specificity of our primer pair for dengue virus requires further
testing with many different flaviviruses, our findings that they can
detect the four dengue virus serotypes but not the other flaviviruses
tested were consistent with our original primer design. The impact and
magnitude of viral loads in concurrent infections with the multiple
dengue virus serotypes that have been documented in both mosquitoes and
humans could therefore be addressed using the QC-RT-PCR assay reported
here (7, 13, 18).
Using in vitro-transcribed RNA as a template, this assay can reliably
detect 10 to 2,000 copies of dengue virus RNA per reaction. The
sensitivity of the assay was estimated to be 10 to 50 copies per
reaction. This assay can be utilized for accurate quantification of
dengue virus RNA derived from stock viruses in the laboratory. The
Hawaii strain of DEN-1 virus was examined, and the results are shown
here. The RNA copy numbers thus determined were higher than the titers
of the virus, with a ratio of around 170. The QC-RT-PCR assay has also
been employed in the quantification of DEN-2, DEN-3, and DEN-4 stock
viruses, and the ratios were found to be in the same range (data not
shown). These findings were in agreement with a recent publication by
Houng et al. in which each infectious PFU of dengue virus was found to
represent at least 100 genomic equivalents (10). Several
factors may account for the discrepancy, one possibility being the
presence of genetically defective viruses due to the error-prone nature
of viral RNA polymerase (20). The sensitivity of flavivirus
envelope to changes in the pH of the medium and the instability or
deterioration of other viral components may also contribute to it
(20). Higher ratios of genome copy numbers to infectious
units have been observed in other viruses, such as human
immunodeficiency virus type 1, where the ratios were found to range
from 104 to 107 (23). This assay can
also be utilized to quantify dengue virus RNA isolated from the plasma
of infected individuals. In this case, plasma samples from two
DEN-3-infected individuals collected during an outbreak in southern
Taiwan in 1998 were tested. The applicability of this assay to the
quantification of a larger number of samples awaits further evaluation.
Compared with RT-PCR-based quantitative methods such as the TaqMan
amplification system, the most important feature of this assay is the
competitive nature of the procedures, which provide stringent internal
control. This is particularly critical for clinical samples, in which
the presence of inhibitors or other variables might affect the kinetics
and efficiency of amplification. Although the TaqMan system was
reported to have a wide range of detection and good sensitivity, it
required four sets of primers, fluorescent dye-labeled probes, and
protocols for different serotypes (16). Our QC-RT-PCR assay
utilized a single primer pair and was able to distinguish between
twofold differences in viral titers. These features make this assay
attractive and suitable for quantitative analysis of clinical samples.
Moreover, combining the RT and PCR into one step is convenient and can
reduce the chance of contamination between samples.
Accurate quantification of plasma viral loads by QC-RT-PCR has been
successfully utilized for other viruses, such as human immunodeficiency
virus type 1 and HCV, and this method has been shown to be useful for
assessing both clinical status and response to therapy (15, 19,
23, 24). Using the virus isolation method, higher dengue viremia
titers were recently reported to correlate with increased disease
severity (28). This is consistent with both the role of
viral virulence and the presence of enhancing antibody in determining
disease severity (8, 11). The relationship between dengue
virus loads in plasma during the course of infection and disease
severity, along with various clinical manifestations, remains to be
elucidated by the more convenient QC-RT-PCR assay developed in this
study. This assay can also be utilized to monitor sequential changes in
viral loads in plasma and to investigate their relationship to the
levels of several immune activation markers that have been reported
recently (6, 8, 11, 27). Findings from such studies may
provide new insights into the pathogenesis of dengue virus infection.
 |
ACKNOWLEDGMENTS |
We thank Shih-Chung Lin at the Kao General Hospital, Ben Jam-Ming
Lee at the Chi-Mei Foundation Hospital, and Shin C. Chang at the
College of Medicine, National Taiwan University, for kindly providing
clinical samples and Dai-Yu Chao for administrative assistance. We also
thank D. J. Gubler for the DEN-1 Hawaii strain and the DEN-2 New
Guinea strain and the National Institute of Preventive Medicine,
Department of Health, Taiwan, for the DEN-4 H-241 strain.
This work was supported in part by the National Science Council
(NSC89-2320-B-002-035) and by the National Health Research Institute
(NHRI-CN-CL8903P), Taiwan, Republic of China.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Microbiology, College of Medicine, National Taiwan University, No.1
Sec.1 Jen-Ai Rd., Taipei, Taiwan. Phone: 886-2-2312-3456, ext. 8286. Fax: 886-2-2391-5293. E-mail: wwang60{at}yahoo.com.
 |
REFERENCES |
| 1.
|
Centers for Disease Control.
1994.
Dengue surveillance United States 1986-1992.
Morbid. Mortal. Weekly Rep.
43(SS-2):7-19.
|
| 2.
|
Chang, G.-J. J.,
D. W. Trent,
A. V. Vorndam,
E. Vergne,
R. M. Kinney, and C. J. Mitchell.
1994.
An integrated target sequence and signal amplification assay, reverse transcriptase-PCR-enzyme-linked-immunosorbent assay, to detect and characterize flaviviruses.
J. Clin. Microbiol.
32:477-483[Abstract/Free Full Text].
|
| 3.
|
Deubel, V.,
R. M. Kinney, and D. W. Trent.
1986.
Nucleotide sequence and deduced amino sequence of the structural proteins of dengue type 2 virus, jamaica genotype.
Virology
155:365-377[CrossRef][Medline].
|
| 4.
|
Deubel, V.
1997.
The contribution of molecular techniques to the diagnosis of dengue infection, p. 335-366.
In
D. J. Gubler, and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, London, United Kingdom.
|
| 5.
|
Freeman, W. M.,
S. J. Walker, and K. E. Vrana.
1999.
Quantitative RT-PCR: pitfalls and potential.
BioTechniques
26:112-125[Medline].
|
| 6.
|
Green, S.,
D. W. Vaughn,
S. Kalayanarooj,
S. Nimmannitya,
S. Suntayakorn,
A. Nisalak,
R. Lew,
B. L. Innis,
I. Kurane,
A. L. Rothman, and F. A. Ennis.
1999.
Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity.
J. Infect. Dis.
179:755-762[CrossRef][Medline].
|
| 7.
|
Gubler, D. J.,
G. Kuno,
G. E. Sather, and S. H. Waterman.
1985.
A case of natural concurrent human infection with two dengue viruses.
Am. J. Trop. Med. Hyg.
34:170-173.
|
| 8.
|
Gubler, D. J.
1998.
Dengue and dengue hemorrhagic fever.
Clin. Microbiol. Rev.
11:480-496[Abstract/Free Full Text].
|
| 9.
|
Harris, E.,
G. Roberts,
L. Smith,
J. Selle,
L. D. Kramer,
S. Valle,
E. Sandoval, and A. Balmaseda.
1998.
Typing of dengue viruses in clinical specimens and mosquitoes by single-tube multiplex reverse transcriptase PCR.
J. Clin. Microbiol.
36:2634-2639[Abstract/Free Full Text].
|
| 10.
|
Houng, H. S. H.,
D. Hritz, and N. Kanesa-thasan.
2000.
Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3'-noncoding sequence.
J. Virol. Methods
86:1-11[CrossRef][Medline].
|
| 11.
|
Innis, B. L.
1995.
Dengue and dengue hemorrhagic fever, p. 103-146.
In
J. S. Porterfield (ed.), Exotic viral infections 1995. Chapman & Hall, London, United Kingdom.
|
| 12.
|
Kuno, G.,
G.-J. J. Chang,
R. Tsuchiya,
N. Karabatsos, and C. B. Cropp.
1998.
Phylogeny of the genus Flavivirus.
J. Virol.
72:73-83[Abstract/Free Full Text].
|
| 13.
|
Laille, M.,
V. Deubel, and F. F. Sainte-Marie.
1991.
Demonstration of concurrent dengue 1 and dengue 3 infection in six patients by the polymerase chain reaction.
J. Med. Virol.
34:51-54[Medline].
|
| 14.
|
Lanciotti, R. S.,
C. H. Calisher,
D. J. Gubler,
G.-J. Chang, and A. V. Vorndam.
1992.
Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction.
J. Clin. Microbiol.
30:545-551[Abstract/Free Full Text].
|
| 15.
|
Lau, J. Y. N.,
G. L. Davis,
J. Kniffen,
K. P. Qian,
M. S. Urdea,
C. S. Chan,
M. Mizokami,
P. D. Neuwald, and J. C. Wilber.
1993.
Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.
Lancet
341:1501-1504[CrossRef][Medline].
|
| 16.
|
Laue, T.,
P. Emmerich, and H. Schmitz.
1999.
Detection of dengue virus RNA in patients after primary or secondary dengue infection by using the TaqMan automated amplification system.
J. Clin. Microbiol.
37:2543-2547[Abstract/Free Full Text].
|
| 17.
|
Lin, Y.-L.,
C.-L. Liao,
L.-K. Chen,
C.-T. Yeh,
C.-I. Liu,
S.-H. Ma,
Y.-Y. Huang,
Y.-L. Huang,
C.-L. Kao, and C.-C. King.
1998.
Study of dengue virus infection in SCID mice engrafted with human K562 cells.
J. Virol.
72:9729-9737[Abstract/Free Full Text].
|
| 18.
|
Lorono-Pino, M. A.,
C. B. Cropp,
J. A. Farfan,
A. V. Vorndam,
E. M. Rodriguez-Angulo,
E. P. Rosado-Paredes,
L. F. Flores-Flores,
B. J. Beaty, and D. J. Gubler.
1999.
Common occurrence of concurrent infections by multiple dengue virus serotypes.
Am. J. Trop. Med. Hyg.
61:725-730[Abstract].
|
| 19.
|
Mellors, J. W.,
C. R. Rinaldo,
P. Gupta,
R. M. White,
J. A. Todd, and L. A. Kinsley.
1996.
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
Science
272:1167-1170[Abstract].
|
| 20.
|
Monath, T. P., and F. X. Heinz.
1996.
Flaviviruses, p. 961-1034.
In
B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology. Lippincott-Raven Publishers, Philadelphia, Pa.
|
| 21.
|
Monath, T. P.
1994.
Dengue, the risk to developed and developing countries.
Proc. Natl. Acad. Sci. USA
91:2395-2400[Abstract/Free Full Text].
|
| 22.
|
Piatak, M.,
K. C. Luk,
B. Williams, and J. D. Lifson.
1993.
Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species.
BioTechniques
14:70-79[Medline].
|
| 23.
|
Piatak, M.,
M. S. Saag,
L. C. Yang,
S. J. Clark,
J. C. Kappes,
K. C. Luk,
B. H. Hahn,
G. M. Shaw, and J. D. Lifson.
1993.
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.
Science
259:1749-1754.
|
| 24.
|
Shiratori, Y.,
N. Kato,
O. Yokosuka,
E. Hashimoto,
N. Hayashi,
A. Nakamura,
M. Asada,
H. Kuroda,
H. Ohkubo,
Y. Arakawa,
A. Iwama, and M. Omata.
1997.
Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.
J. Hepatol.
27:437-444[CrossRef][Medline].
|
| 25.
|
Souaze, F.,
A. Ntodou-Thome,
C. Y. Tran,
W. Rostene, and P. Forgez.
1996.
Quantitative RT-PCR: limits and accuracy.
BioTechniques
21:280-285[Medline].
|
| 26.
|
Sudiro, T. M.,
H. Ishiko,
S. Green,
D. W. Vaughn,
A. Nisalak,
S. Kalayanarooj,
A. L. Rothman,
B. Raengsakulrach,
J. Janus,
I. Kurane, and F. A. Ennis.
1997.
Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers.
Am. J. Trop. Med. Hyg.
56:424-429.
|
| 27.
|
Vaughn, D. W.,
S. Green,
S. Kalayanarooj,
B. L. Innis,
S. Nimmannitya,
S. Suntayakorn,
A. L. Rothman,
F. A. Ennis, and A. Nisalak.
1997.
Dengue in the early febrile phase: viremia and antibody responses.
J. Infect. Dis.
176:322-330[Medline].
|
| 28.
|
Vaughn, D. W.,
S. Green,
S. Kalayanarooj,
B. L. Innis,
S. Nimmannitya,
S. Suntayakorn,
T. P. Endy,
B. Raengsakulrach,
A. L. Rothman,
F. A. Ennis, and A. Nisalak.
2000.
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.
J. Infect. Dis.
181:2-9[CrossRef][Medline].
|
| 29.
|
Vorndam, V., and G. Kuno.
1997.
Laboratory diagnosis of dengue virus infections, p. 313-334.
In
D. J. Gubler, and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, London, United Kingdom.
|
| 30.
|
World Health Organization.
1986.
Dengue hemorrhagic fever, diagnosis, treatment and control.
World Health Organization, Geneva, Switzerland.
|
Journal of Clinical Microbiology, September 2000, p. 3306-3310, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Boonnak, K., Slike, B. M., Burgess, T. H., Mason, R. M., Wu, S.-J., Sun, P., Porter, K., Rudiman, I. F., Yuwono, D., Puthavathana, P., Marovich, M. A.
(2008). Role of Dendritic Cells in Antibody-Dependent Enhancement of Dengue Virus Infection. J. Virol.
82: 3939-3951
[Abstract]
[Full Text]
-
Kleiboeker, S. B.
(2003). Applications of Competitor RNA in Diagnostic Reverse Transcription-PCR. J. Clin. Microbiol.
41: 2055-2061
[Abstract]
[Full Text]
-
Wang, W.-K., Sung, T.-L., Tsai, Y.-C., Kao, C.-L., Chang, S.-M., King, C.-C.
(2002). Detection of Dengue Virus Replication in Peripheral Blood Mononuclear Cells from Dengue Virus Type 2-Infected Patients by a Reverse Transcription-Real-Time PCR Assay. J. Clin. Microbiol.
40: 4472-4478
[Abstract]
[Full Text]
-
Wang, W.-K., Lin, S.-R., Lee, C.-M., King, C.-C., Chang, S.-C.
(2002). Dengue Type 3 Virus in Plasma Is a Population of Closely Related Genomes: Quasispecies. J. Virol.
76: 4662-4665
[Abstract]
[Full Text]